VACCINE RESULTS: DEFENCE
THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE
ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS
Vancouver, BC,
Canada, November 3rd,
2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc.
CSE:DTC,
USOTC:DTCFF ("Defence"
or the "Company"),
a biotechnology company working on the development of next
generation cancer therapeutics and infectious disease vaccines is
pleased to announce the successful completion of its protein-based
COVID vaccine (AccuVAC-PT001) toxicology studies in non-rodent
rabbit model.
The AccuVAC-PT001 vaccine is an injectable vaccine capable of
inducing a powerful and sustainable antibody response in both
rodent and non-rodent models. The vaccine proprietary recipe
consists of chemically modifying the COVID Spike protein with the
AccumTM
moiety. Once delivered in animals, the protein accumulates very
efficiently in target antigen presenting cells leading to extremely
high antibody titers. Extensive analyses conducted on vaccinated
rabbits showed no effects induced by the vaccine on animal
behaviour, food intake, body weight, skin at injected sites and
liver enzymatic function amongst other investigated organs. Defence
is currently working on two different protein-based vaccine
candidates.
"We are continuously working to move our lead compounds forward to
bring products with stronger and more precise efficacy. The
AccuVAC-PT001 is one the two COVID vaccines currently being
developed in parallel by our team. A GLP study is currently
underway and is one of the few remaining steps needed to fulfill
all the requirements of regulatory agencies prior to initiate a
Phase I trial in 2022", says Mr. Plouffe, CEO of Defence
Therapeutics.
Defence Therapeutics is currently working on developing both a
vaccine to block COVID infection and pathophysiology as well as an
intranasally-delivered vaccine designed to completely block viral
transmission. The developed "know-how" combined to the versatility
of the AccumTM
technology position Defence as a leading biotech company with its
AccumTM
platform to rapidly face current and future possible pandemics
based on both injectable and non-invasive vaccine
formulations.
Additional
Information:
The Company makes no
express or implied claims that it has developed a vaccine to treat
COVID-19 (or SARS-2 Coronavirus) at this time.
Dr. Moutih Rafei,
Defence's VP Research and Development, has reviewed and approved
the scientific disclosure contained in this press
release.
Dr. Rafei has a PhD in
Experimental Medicine from McGill University and received his
post-doctoral training at Université de Montréal. He is an
immuno-oncologist who specializes in the fields of T-cell
development, stem cell biology, cancer immunotherapy and autoimmune
diseases.
About
Defence:
Defence
Therapeutics is a publicly-traded biotechnology company working on
engineering the next generation vaccines and ADC products using its
proprietary platform. The
core of Defence Therapeutics platform is the ACCUMTM
technology,
which enables precision delivery of vaccine antigens or ADCs in
their intact form to target cells. As a result, increased efficacy
and potency can be reached against catastrophic illness such as
cancer and infectious diseases.
For further
information:
Sebastien Plouffe,
President, CEO and Director
P: (514)
947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary
Statement Regarding "Forward-Looking" Information
This release includes
certain statements that may be deemed "forward-looking statements".
All statements in this release, other than statements of historical
facts, that address events or developments that the Company expects
to occur, are forward-looking statements. Forward-looking
statements are statements that are not historical facts and are
generally, but not always, identified by the words "expects",
"plans", "anticipates", "believes", "intends", "estimates",
"projects", "potential" and similar expressions, or that events or
conditions "will", "would", "may", "could" or "should" occur.
Although the Company believes the expectations expressed in such
forward-looking statements are based on reasonable assumptions,
such statements are not guarantees of future performance and actual
results may differ materially from those in the forward-looking
statements. Factors that could cause the actual results to differ
materially from those in forward-looking statements include
regulatory actions, market prices, and continued availability of
capital and financing, and general economic, market or business
conditions. Investors are cautioned that any such statements are
not guarantees of future performance and actual results or
developments may differ materially from those projected in the
forward-looking statements. Forward-looking statements are based on
the beliefs, estimates and opinions of the Company's management on
the date the statements are made. Except as required by applicable
securities laws, the Company undertakes no obligation to update
these forward-looking statements in the event that management's
beliefs, estimates or opinions, or other factors, should
change.
Neither the
CSE nor its market regulator, as that term is defined in the
policies of the CSE, accepts responsibility for the adequacy or
accuracy of this release.
